Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4327758 | 1.00 | KEAP1 (0.31) | KEAP1NFE2L2SMYD2 | |
| SCHEMBL3621050 | 0.84 | SMYD2 (0.31) | SMYD2 | |
| SCHEMBL3621048 | 0.84 | SMYD2 (0.31) | SMYD2 | |
| SCHEMBL4089186 | 0.84 | SMYD2 (0.31) | SMYD2 | |
| SCHEMBL4093529 | 0.83 | KDM4E (0.32) | SMYD2 | |
| SCHEMBL4082948 | 0.77 | SMYD2 (0.33) | SMYD2 | |
| SCHEMBL4328118 | 0.76 | HSD11B1 (0.33) | KEAP1NFE2L2SMYD2 | |
| SCHEMBL4328114 | 0.76 | HSD11B1 (0.33) | KEAP1NFE2L2SMYD2 | |
| SCHEMBL4058932 | 0.75 | KEAP1 (0.32) | KEAP1NFE2L2 | |
| SCHEMBL4058931 | 0.75 | KEAP1 (0.32) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737141-B2 | such as -{4-{1-[(S)-1-(4-fluorophenyl)ethyl]-2-oxopiperidin-(3E)-ylidenemethyl}-2-methoxyphenyl}-5-methyl-1-(phosphonooxymethyl)-3H-imidazol-1-ium trifluoroacetate, which inhibit the synthesis of amyloid precursor proteins; treatment of Alzheimer's disease, Down syndrome or amyloidosis | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090203781-A1 | N-N-Acyloxypropyl Lysine Methyl Ester-and N,N-Bis(N-Acyloxypropyl) Lysine Methyl Ester-Type Compounds and Use Thereof as Surface-Active Agents with an Antimicrobial Activity | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICSA (ES) | 2009-08-13 | — | — | US | disclosed |
| EP-2048143-A1 | PRODRUG OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090048213-A1 | Prodrug of cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2009-02-19 | — | — | US | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1813600-A1 | N-N-ACYLOXYPROPYL LYSINE METHYL ESTER- AND N,N-BIS(N- ACYLOXYPROPYL)LYSINE METHYL ESTER-TYPE COMPOUNDS AND USE THEREOF AS SURFACE-ACTIVE AGENTS WITH AN ANTIMICROBIAL ACTIVITY | Consejo Superior de Investigaciones Cientificas (ES) | 2007-08-01 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | KEAP1 217/4885NFE2L2 418/4885SMYD2 3033/4885 |
| US-20090048213-A1 | Prodrug of cinnamide compound | BTK, CNKSR1, AKT1 | KEAP1 954/4885NFE2L2 2810/4885SMYD2 3568/4885 |
| US-20090203781-A1 | N-N-Acyloxypropyl Lysine Methyl Ester-and N,N-Bis(N-Acyloxypropyl) Lysine Methyl Ester-Type Compounds and Use Thereof as Surface-Active Agents with an Antimicrobial Activity | APEH, CUTA, NAAA | KEAP1 4027/4885NFE2L2 4029/4885SMYD2 165/4885 |
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | KEAP1 520/4885NFE2L2 1925/4885SMYD2 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.